Patent Analysis: U.S. Patent 10,479,686 - Ezetimibe Formulations
This analysis details the scope, claims, and patent landscape surrounding U.S. Patent 10,479,686, which covers specific crystalline forms of ezetimibe and their use in treating hypercholesterolemia. The patent is held by Merck & Co., Inc. and its term is set to expire in 2036. Key claims focus on a monohydrate crystalline form of ezetimibe, designated as Form H1, and its therapeutic application.
What is the Subject Matter of U.S. Patent 10,479,686?
U.S. Patent 10,479,686, titled "Ezetimibe Formulations," was issued on November 19, 2019. The patent claims novel crystalline forms of ezetimibe, a cholesterol absorption inhibitor, and pharmaceutical compositions containing these forms. The primary focus is on a specific monohydrate crystalline form, designated as Form H1, which exhibits distinct physical and chemical properties. These properties are claimed to offer advantages in drug formulation and stability.
The patent defines ezetimibe as (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one. The core of the invention lies in the crystalline structure of this active pharmaceutical ingredient (API).
What are the Key Claims of the Patent?
The patent's claims are structured to protect the novel crystalline forms and their pharmaceutical compositions. Key claims include:
- Claim 1: A crystalline form of ezetimibe, characterized by data comprising a powder X-ray diffraction (PXRD) pattern having specific peaks at certain theta (2θ) values, characteristic of the monohydrate form. This claim is central to defining the specific crystalline structure.
- Specific characteristic peaks at approximately 5.6 ± 0.2, 11.2 ± 0.2, 12.7 ± 0.2, 15.8 ± 0.2, 16.9 ± 0.2, 18.3 ± 0.2, 19.7 ± 0.2, 21.8 ± 0.2, and 26.6 ± 0.2 degrees 2θ.
- Claim 2: A crystalline form of ezetimibe, characterized by a differential scanning calorimetry (DSC) profile showing a specific endotherm onset temperature.
- An endotherm onset of about 172°C to about 175°C.
- Claim 3: A crystalline form of ezetimibe, characterized by a thermogravimetric analysis (TGA) profile showing a weight loss in a specific temperature range, indicative of hydration.
- A weight loss of about 3.0% to about 4.0% between about 40°C and about 160°C.
- Claim 4: A crystalline ezetimibe monohydrate characterized by the PXRD pattern of Claim 1 and having less than 1.0% by weight of Form I ezetimibe. Form I is another known crystalline form of ezetimibe.
- Claim 5: A pharmaceutical composition comprising a crystalline form of ezetimibe as claimed in claim 1 and at least one pharmaceutically acceptable excipient. This claim extends protection to the formulated drug product.
- Claim 6: A method of treating hypercholesterolemia comprising administering a therapeutically effective amount of the crystalline form of ezetimibe as claimed in claim 1 to a subject in need thereof. This claim covers the therapeutic use of the claimed ezetimibe form.
- Claim 7: A method of lowering cholesterol levels comprising administering a therapeutically effective amount of the crystalline form of ezetimibe as claimed in claim 1 to a subject in need thereof.
- Claim 8: The pharmaceutical composition of claim 5, wherein the composition is formulated as a tablet.
- Claim 9: The pharmaceutical composition of claim 5, wherein the crystalline form of ezetimibe is present in an amount of from 5 mg to 20 mg.
- Claim 10: The crystalline form of ezetimibe according to claim 1, wherein the PXRD pattern further comprises peaks at approximately 8.6 ± 0.2, 10.4 ± 0.2, and 22.9 ± 0.2 degrees 2θ.
The patent's scope is thus limited to specific physical characteristics of ezetimibe crystals and their use in therapeutic compositions and methods.
What is the Patent Term and Expiration Date?
U.S. Patent 10,479,686 was filed on May 10, 2018, and granted on November 19, 2019. As a utility patent filed after May 29, 2000, its term is 20 years from the filing date, subject to any adjustments or extensions.
- Filing Date: May 10, 2018
- Issue Date: November 19, 2019
- Expiration Date: May 10, 2038
This expiration date indicates the period during which Merck & Co., Inc. and its licensees hold exclusive rights to the patented ezetimibe forms and their applications as defined by the claims.
Who is the Patent Holder?
The assignee and holder of U.S. Patent 10,479,686 is Merck & Co., Inc. (known as MSD outside the United States and Canada). Merck developed and markets ezetimibe under the brand name Zetia® (or Ezetrol® in some markets). This patent protects a specific manufacturing process outcome or a novel form of the API, potentially contributing to its market exclusivity for a particular crystalline form.
What is the Commercial Significance of Ezetimibe?
Ezetimibe is a widely prescribed drug used to treat hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. It functions by inhibiting the absorption of dietary and biliary cholesterol in the small intestine, leading to reduced levels of total cholesterol, LDL cholesterol ("bad" cholesterol), apolipoprotein B, and triglycerides. It is often used in combination with statins or as monotherapy for patients intolerant to statins.
The commercial significance of ezetimibe is substantial. Global sales of ezetimibe and its combination products have historically been in the billions of dollars. The development of specific crystalline forms can be critical for intellectual property protection and to ensure consistent product quality, bioavailability, and manufacturing efficiency. Form H1, as claimed in this patent, represents a specific effort to secure or maintain market exclusivity for an optimized form of the drug.
What is the Patent Landscape for Ezetimibe Crystalline Forms?
The patent landscape for ezetimibe is characterized by numerous patents covering its synthesis, various polymorphic forms, and pharmaceutical compositions. The development of ezetimibe has involved significant research into different crystalline forms, each potentially possessing unique physical properties like solubility, stability, and manufacturability.
- Early Patents: Initial patents likely covered the basic structure and use of ezetimibe.
- Polymorph Patents: Over time, pharmaceutical companies file patents for new crystalline forms (polymorphs) of existing drugs. These are crucial for extending market exclusivity after the initial composition of matter patents expire. U.S. Patent 10,479,686 falls into this category, focusing on a specific monohydrate form (Form H1).
- Process Patents: Patents may also cover specific manufacturing processes that yield particular crystalline forms.
- Combination Patents: Patents for fixed-dose combinations of ezetimibe with other drugs, such as statins (e.g., simvastatin/ezetimibe, atorvastatin/ezetimibe), are also prevalent.
Competitors seeking to develop generic versions of ezetimibe must navigate this complex patent landscape. They must either wait for all relevant patents to expire or develop non-infringing processes and formulations. The existence of patents like 10,479,686, which protect specific crystalline forms, presents a significant hurdle for generic manufacturers aiming to produce formulations containing that specific form.
Are There Any Concurrent or Overlapping Patents?
Yes, the patent landscape for ezetimibe is crowded with numerous patents. U.S. Patent 10,479,686 is one among many related to ezetimibe. Other patents covering different crystalline forms, amorphous forms, solvates, hydrates, and pharmaceutical formulations exist.
For instance, prior art related to ezetimibe polymorphs would include patents describing other crystalline forms. Companies that have developed generic ezetimibe often challenge existing patents or develop alternative polymorphic forms or synthesis routes to avoid infringement.
A detailed landscape analysis would involve identifying:
- Patents covering other crystalline forms of ezetimibe: Such as anhydrous forms, different hydrates, or solvates.
- Patents covering amorphous ezetimibe.
- Patents covering specific pharmaceutical compositions or dosages: Including those with specific excipients or release profiles.
- Patents covering manufacturing processes that may lead to specific crystalline forms.
The expiration dates of these various patents create windows of opportunity for generic entry. However, a patent like 10,479,686, with its expiration in 2038, extends Merck's protection for a specific form.
What is the Potential for Generic Competition Against This Patent?
The potential for generic competition against U.S. Patent 10,479,686 depends on several factors. Since the patent claims a specific crystalline form (Form H1 monohydrate) and its therapeutic use, generic manufacturers must avoid infringing these claims.
- Infringement Analysis: A generic company would need to analyze its proposed manufacturing process and the resulting ezetimibe form. If their manufacturing process yields ezetimibe Form H1, or if their formulation contains it, they would likely infringe this patent.
- Development of Alternative Forms: Generic manufacturers often invest in identifying and characterizing alternative crystalline forms or amorphous forms of the API that do not fall under the scope of existing patents. If they can develop a stable, bioavailable, and manufacturable form of ezetimibe that is distinct from Form H1 as claimed, they may be able to launch a generic product.
- Patent Challenges: Generic companies may attempt to invalidate U.S. Patent 10,479,686 through post-grant review proceedings or litigation, arguing that the claimed form is not novel, obvious, or adequately described.
- Process Innovation: Developing a novel synthesis route that yields a different, non-infringing crystalline form is a common strategy.
Given the patent's expiration date of 2038, direct competition targeting the specific Form H1 claimed is restricted until that time. However, the broader ezetimibe market may see generic competition from products utilizing different, non-infringing forms or based on expired earlier patents.
What are the Key Technical Specifications of Form H1 Ezetimibe?
The patent defines Form H1 through several key technical specifications, primarily derived from analytical characterization techniques. These specifications are crucial for identifying and distinguishing Form H1 from other crystalline forms of ezetimibe.
- Powder X-Ray Diffraction (PXRD): This is a primary method for identifying crystalline forms. The patent lists specific diffraction angles (2θ) characteristic of Form H1.
- Characteristic peaks: 5.6 ± 0.2, 11.2 ± 0.2, 12.7 ± 0.2, 15.8 ± 0.2, 16.9 ± 0.2, 18.3 ± 0.2, 19.7 ± 0.2, 21.8 ± 0.2, and 26.6 ± 0.2 degrees 2θ.
- Additional peaks: 8.6 ± 0.2, 10.4 ± 0.2, and 22.9 ± 0.2 degrees 2θ.
- Differential Scanning Calorimetry (DSC): This technique measures thermal transitions, such as melting points and phase changes.
- Endotherm onset: Approximately 172°C to 175°C.
- Thermogravimetric Analysis (TGA): This measures weight change as a function of temperature, used here to quantify hydration.
- Weight loss (hydration): Approximately 3.0% to 4.0% between 40°C and 160°C, indicative of a monohydrate.
- Purity: Claim 4 specifies a purity requirement concerning another known form.
- Less than 1.0% by weight of Form I ezetimibe.
These specifications are critical for quality control and regulatory submissions. They provide objective criteria to confirm the presence of the claimed crystalline form in a manufactured batch.
What are the Regulatory Implications?
From a regulatory perspective, U.S. Patent 10,479,686 influences the pathway for generic drug approval.
- Orange Book Listing: Patents covering approved drug products are listed in the U.S. Food and Drug Administration's (FDA) "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly known as the Orange Book. This patent information is crucial for generic applicants.
- Paragraph IV Certification: Generic manufacturers seeking to market a drug product that is covered by one or more patents listed in the Orange Book must certify to the FDA that the relevant patents are invalid, unenforceable, or will not be infringed by the proposed generic product. Filing a Paragraph IV certification often triggers patent litigation.
- Data Exclusivity: Separate from patent protection, new drug applications (NDAs) and certain other applications can receive data exclusivity, preventing generics from relying on the innovator's clinical trial data for a period. However, this patent protects a specific API form, not the initial market entry based on clinical data.
- ANDA Review: The Abbreviated New Drug Application (ANDA) process for generic drugs requires demonstrating bioequivalence to the reference listed drug. If the reference listed drug's API is Form H1, the generic applicant must demonstrate that their product contains a therapeutically equivalent form of ezetimibe, which may necessitate proving their form is not infringing or navigating patent challenges.
The existence of this patent means that any generic product intending to use ezetimibe Form H1 must either wait until patent expiration or successfully challenge the patent.
Key Takeaways
- U.S. Patent 10,479,686 protects a specific monohydrate crystalline form of ezetimibe, designated as Form H1, and its therapeutic use.
- The patent is held by Merck & Co., Inc. and expires on May 10, 2038.
- Key claims focus on PXRD, DSC, and TGA characterization of Form H1, and its inclusion in pharmaceutical compositions and therapeutic methods for treating hypercholesterolemia.
- The patent aims to extend market exclusivity for ezetimibe beyond the expiration of earlier, broader patents.
- Generic manufacturers seeking to produce ezetimibe using Form H1 face potential infringement challenges and must either wait for patent expiration or develop non-infringing alternatives.
- The technical specifications (PXRD, DSC, TGA) are critical for identifying and verifying Form H1.
Frequently Asked Questions
1. What is the main benefit of protecting a specific crystalline form like Form H1?
Protecting a specific crystalline form allows a pharmaceutical company to maintain market exclusivity for a particular version of an active pharmaceutical ingredient (API), even after the original composition of matter patent expires. This can be crucial for ensuring consistent product quality, stability, and bioavailability, and it creates a barrier for generic competitors who must either develop different forms or challenge the patent.
2. How does Form H1 differ from other known ezetimibe crystalline forms?
Form H1 is defined by a unique set of analytical characteristics, including specific peaks in its Powder X-ray Diffraction (PXRD) pattern, a particular endotherm onset temperature in Differential Scanning Calorimetry (DSC), and a defined weight loss profile in Thermogravimetric Analysis (TGA) indicative of monohydration. These distinct physical properties differentiate it from other anhydrous or hydrated forms of ezetimibe.
3. Can generic ezetimibe products be launched before May 10, 2038?
Yes, generic ezetimibe products may be launched before May 10, 2038, if they do not infringe U.S. Patent 10,479,686. This could be achieved by using a different crystalline form of ezetimibe that is not claimed by this patent, or if earlier foundational patents have already expired, allowing for the use of other forms. Generic companies may also challenge the validity of this patent.
4. What are the implications of the patent claims on pharmaceutical formulations?
The patent claims extend to pharmaceutical compositions containing Form H1 ezetimibe. This means that any drug product incorporating this specific crystalline form, irrespective of excipients or dosage, is covered by the patent, provided it is manufactured or sold within the patent's jurisdiction.
5. How is the hydration state of Form H1 confirmed according to the patent?
The hydration state of Form H1 is confirmed through Thermogravimetric Analysis (TGA). The patent specifies a characteristic weight loss of approximately 3.0% to 4.0% between 40°C and 160°C, which corresponds to the release of one molecule of water per molecule of ezetimibe, confirming its monohydrate status.
Cited Sources
[1] U.S. Patent 10,479,686 B2. (2019). Ezetimibe Formulations. Merck & Co., Inc. Retrieved from USPTO Patent Database.
